Novo Nordisk has unveiled promising data for its higher dose Wegovy injection, which could enhance its competitive edge against Eli Lilly’s Zepbound in the obesity treatment market. In a late-stage trial, patients receiving the 7.2-milligram dose of Wegovy lost an average of 27.7% of their weight over 72 weeks, significantly outperforming the previous 2.4-milligram version, which yielded a 17% weight loss. This new dosage is already being adopted by major pharmacy benefit managers, indicating a positive reception in the market.
The implications for the financial markets are substantial, as Wegovy’s enhanced efficacy may help Novo regain market share from Zepbound, which has established itself as a leading obesity drug with over 20% average weight loss in trials. However, the variability in patient responses and the uncertainty surrounding the effectiveness of Zepbound’s early responders complicate direct comparisons.
Investors should monitor the uptake of the 7.2-milligram dose and its impact on Novo’s market position, as well as the ongoing competitive dynamics with Eli Lilly.
Source: cnbc.com